抗真菌治療薬市場は174億ドルに達すると予想され、世界的な真菌感染症の発生の増加により、メーカーはより良い臨床転帰を目指して強化された製剤の開発を推進しているため、3.3%のCAGRで成長する見込みです。これにより、予測期間全体を通じて市場の拡大が促進されます。その結果、メーカーはナノテクノロジーを利用して製造できる新しい医薬品製剤に注目しています。
								
						目次
						
	Table of Content
	
	Table of Content
	1. Executive Summary
	
	1.1. Regional Market Share
	1.2. Business Trends
	1.3. Anti-Fungal Treatment Market: COVID-19 Outbreak
	1.4. Regional Trends
	1.5. Segmentation Snapshot
	2. Research Methodology
	
	2.1. Research Objective
	2.2. Research Approach
	2.3. Data Sourcing and Methodology
	2.4. Primary Research
	2.5. Secondary Research
	2.5.1. Paid Sources
	2.5.2. Public Sources
	2.6. Market Size Estimation and Data Triangulation
	3. Market Characteristics
	
	3.1. Market Definition
	3.2. Anti-Fungal Treatment Market: COVID-19 Impact
	3.3. Key Segmentations
	3.4. Key Developments
	3.5. Allied Industry Data
	4. Anti-Fungal Treatment Market - Industry Insights
	
	4.1. Industry Segmentation
	4.2. COVID-19 overview on world economy
	4.3. Industry ecosystem Channel analysis
	4.4. Innovation & Sustainability
	5. Macroeconomic Indicators
	6. Recent Developments
	7. Market Dynamics
	
	7.1. Introduction
	7.2. Growth Drivers
	7.3. Market Opportunities
	7.4. Market Restraints
	7.5. Market Trends
	8. Risk Analysis
	9. Market Analysis
	
	9.1. Porters Five Forces
	9.2. PEST Analysis
	9.2.1. Political
	9.2.2. Economic
	9.2.3. Social
	9.2.4. Technological
	10. Anti-Fungal Treatment Market
	
	10.1. Overview
	10.2. Historical Analysis (2019-2021)
	10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
	11. Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
	
	11.1. Overview
	11.2. Key Findings
	11.3. Market Segmentation
	11.3.1. By Drug Type
	11.3.1.1. Echinocandins
	11.3.1.1.1. By Value (USD Million) 2022-2032F
	11.3.1.1.2. Market Share (%) 2022-2032F
	11.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
	11.3.1.2. Azoles
	11.3.1.2.1. By Value (USD Million) 2022-2032F
	11.3.1.2.2. Market Share (%) 2022-2032F
	11.3.1.2.3. Y-o-Y Growth (%) 2022-2032F
	11.3.1.3. Polyenes
	11.3.1.3.1. By Value (USD Million) 2022-2032F
	11.3.1.3.2. Market Share (%) 2022-2032F
	11.3.1.3.3. Y-o-Y Growth (%) 2022-2032F
	11.3.1.4. Allylamines
	11.3.1.4.1. By Value (USD Million) 2022-2032F
	11.3.1.4.2. Market Share (%) 2022-2032F
	11.3.1.4.3. Y-o-Y Growth (%) 2022-2032F
	11.3.2. By Indication
	11.3.2.1. Dermatophytosis
	11.3.2.1.1. By Value (USD Million) 2022-2032F
	11.3.2.1.2. Market Share (%) 2022-2032F
	11.3.2.1.3. Y-o-Y Growth (%) 2022-2032F
	11.3.2.2. Aspergillosis
	11.3.2.2.1. By Value (USD Million) 2022-2032F
	11.3.2.2.2. Market Share (%) 2022-2032F
	11.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
	11.3.2.3. Candidiasis
	11.3.2.3.1. By Value (USD Million) 2022-2032F
	11.3.2.3.2. Market Share (%) 2022-2032F
	11.3.2.3.3. Y-o-Y Growth (%) 2022-2032F
	11.3.2.4. Others
	11.3.2.4.1. By Value (USD Million) 2022-2032F
	11.3.2.4.2. Market Share (%) 2022-2032F
	11.3.2.4.3. Y-o-Y Growth (%) 2022-2032F
	11.3.3. By Route of Administration
	11.3.3.1 Oral
	11.3.3.1.1By Value (USD Million) 2022-2032F
	11.3.3.1.2 Market Share (%) 2022-2032F
	11.3.3.1.3 Y-o-Y Growth (%) 2022-2032F
	11.3.3.2Topical
	11.3.3.2.1 By Value (USD Million) 2022-2032F
	11.3.3.2.2Market Share (%) 2022-2032F
	11.3.3.3.1 Y-o-Y Growth (%) 2022-2032F
	11.3.3.3Parenteral
	11.3.3.3.1 By Value (USD Million) 2022-2032F
	11.3.4.1.2 Market Share (%) 2022-2032F
	11.3.4.1.3 Y-o-Y Growth (%) 2022-2032F
	11.3.4 By Distribution Channel
	11.3.4.1 Hospital Pharmacies
	11.3.4.1.1By Value (USD Million) 2022-2032F
	11.3.4.1.2 Market Share (%) 2022-2032F
	11.3.4.1.3 Y-o-Y Growth (%) 2022-2032F
	11.3.4.2Retail Pharmacies & Drug Store
	11.3.4.2.1 By Value (USD Million) 2022-2032F
	11.3.4.2.2Market Share (%) 2022-2032F
	11.3.4.2.3Y-o-Y Growth (%) 2022-2032F
	11.3.4.3Others
	11.3.4.3.1 By Value (USD Million) 2022-2032F
	11.3.4.3.2Market Share (%) 2022-2032F
	11.3.4.3.3Y-o-Y Growth (%) 2022-2032F
	12. North America Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
	
	12.1. Overview
	12.2. Key Findings
	12.3. Market Segmentation
	12.3.1. By Drug Type
	12.3.2. By Indication
	12.3.3. By Route of Administration
	12.3.4. By Distribution Channel
	12.4. Country
	12.4.1. United States
	12.4.2. Canada
	13. Europe Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
	
	13.1. Overview
	13.2. Key Findings
	13.3. Market Segmentation
	13.3.1. By Drug Type
	13.3.2. By Indication
	13.3.3. By Route of Administration
	13.3.4. By Distribution Channel
	13.4. Country
	13.4.1. Germany
	13.4.2. United Kingdom
	13.4.3. France
	13.4.4. Italy
	13.4.5. Spain
	13.4.6. Russia
	13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
	14. Asia-Pacific Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
	
	14.1. Overview
	14.2. Key Findings
	14.3. Market Segmentation
	14.3.1. By Drug Type
	14.3.2. By Indication
	14.3.3. By Route of Administration
	14.3.4. By Distribution Channel
	14.4. Country
	14.4.1. India
	14.4.2. China
	14.4.3. South Korea
	14.4.4. Japan
	14.4.5. Rest of APAC
	15. Middle East and Africa Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
	
	15.1. Overview
	15.2. Key Findings
	15.3. Market Segmentation
	15.3.1. By Drug Type
	15.3.2. By Indication
	15.3.3. By Route of Administration
	15.3.4. By Distribution Channel
	15.4. Country
	15.4.1. Israel
	15.4.2. GCC
	15.4.3. North Africa
	15.4.4. South Africa
	15.4.5. Rest of Middle East and Africa
	16. Latin America Anti-Fungal Treatment Market Size & Forecast 2022A-2032F
	
	16.1. Overview
	16.2. Key Findings
	16.3. Market Segmentation
	16.3.1. By Drug Type
	16.3.2. By Indication
	16.3.3. By Route of Administration
	16.3.4. By Distribution Channel
	16.4. Country
	16.4.1. Mexico
	16.4.2. Brazil
	16.4.3. Rest of Latin America
	17. Competitive Landscape
	
	17.1. Company market share, 2021
	17.2. Key player overview
	17.3. Key stakeholders
	18. Company Profiles
	
	18.1. Pfizer Inc.
	18.1.1. Company Overview
	18.1.2. Financial Overview
	18.1.3. Key Product; Analysis
	18.1.4. Company Assessment
	18.1.4.1. Product Portfolio
	18.1.4.2. Key Clients
	18.1.4.3. Market Share
	18.1.4.4. Recent News & Development (Last 3 Yrs.)
	18.1.4.5. Executive Team
	18.2. Novartis AG
	18.3. Gilead Sciences, Inc.
	18.4. Merck & Co., Inc.
	18.5. Johnson & Johnson
	18.6. Astellas Pharma Inc.
	18.7. GlaxoSmithKline plc.
	18.8. AbbVie Inc.
	18.9. Eli Lilly and Company
	18.10. Bristol-Myers Squibb Company
	18.11. Sanofi S. A.
	18.12. Bayer AG
	18.13. Teva Pharmaceutical Industries Ltd.
	18.14. Mylan N. V.
	18.15. Basilea Pharmaceutica AG
	18.16. Other Prominent Players
	19. Appendix
	20. Consultant Recommendation